Clinical Trial Update: Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating eribulin mesylate in combination with gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy for lo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• ERIBULIN MESYLATE (Eribulin mesylate)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Eisai Inc. | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-02-28